Arbutus Biopharma Corp (NASDAQ:ABUS) has earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the company. Two research analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $8.00.

Several equities analysts recently issued reports on ABUS shares. Bloom Burton raised Arbutus Biopharma Corp from an “accumulate” rating to a “buy” rating in a research report on Monday, January 9th. Zacks Investment Research cut Arbutus Biopharma Corp from a “hold” rating to a “sell” rating in a research report on Friday, January 27th. Wedbush reaffirmed an “outperform” rating and issued a $10.00 price objective (up from $9.00) on shares of Arbutus Biopharma Corp in a research report on Wednesday, March 22nd. Finally, Chardan Capital raised Arbutus Biopharma Corp from a “neutral” rating to a “buy” rating and upped their price objective for the company from $3.00 to $6.00 in a research report on Tuesday, April 4th.

ILLEGAL ACTIVITY WARNING: “Analysts Set Arbutus Biopharma Corp (ABUS) PT at $8.00” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/04/21/analysts-set-arbutus-biopharma-corp-abus-pt-at-8-00.html.

Large investors have recently made changes to their positions in the stock. K2 Principal Fund L.P. raised its stake in shares of Arbutus Biopharma Corp by 69.3% in the third quarter. K2 Principal Fund L.P. now owns 107,620 shares of the biopharmaceutical company’s stock worth $370,000 after buying an additional 44,070 shares in the last quarter. Oxford Asset Management bought a new stake in shares of Arbutus Biopharma Corp during the fourth quarter worth $392,000. Baker BROS. Advisors LP bought a new stake in shares of Arbutus Biopharma Corp during the third quarter worth $621,000. Bank of Montreal Can raised its stake in shares of Arbutus Biopharma Corp by 6.3% in the third quarter. Bank of Montreal Can now owns 861,553 shares of the biopharmaceutical company’s stock worth $2,964,000 after buying an additional 50,768 shares in the last quarter. Finally, Armistice Capital LLC raised its stake in shares of Arbutus Biopharma Corp by 38.6% in the fourth quarter. Armistice Capital LLC now owns 1,940,000 shares of the biopharmaceutical company’s stock worth $4,753,000 after buying an additional 540,000 shares in the last quarter. Institutional investors and hedge funds own 61.24% of the company’s stock.



Shares of Arbutus Biopharma Corp (NASDAQ:ABUS) remained flat at $3.35 on Tuesday. The company had a trading volume of 187,149 shares. The firm has a 50-day moving average of $3.10 and a 200 day moving average of $2.88. Arbutus Biopharma Corp has a 52-week low of $2.35 and a 52-week high of $5.48. The company’s market capitalization is $184.33 million.

Arbutus Biopharma Corp Company Profile

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

5 Day Chart for NASDAQ:ABUS

Receive News & Stock Ratings for Arbutus Biopharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma Corp and related stocks with our FREE daily email newsletter.